CN Patent

CN118459504A — 一种巴瑞替尼衍生物及其制备方法与用途

Assigned to Nanjing Zhihe Medical Technology Co ltd · Expires 2024-08-09 · 2y expired

What this patent protects

本发明公开了一种巴瑞替尼衍生物及其制备方法与用途，该类衍生物在提高水溶性、增强用药安全性、提高疗效、增加药物耐受性方面具有显著的优越性，具有广阔的开发前景。

USPTO Abstract

本发明公开了一种巴瑞替尼衍生物及其制备方法与用途，该类衍生物在提高水溶性、增强用药安全性、提高疗效、增加药物耐受性方面具有显著的优越性，具有广阔的开发前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN118459504A
Jurisdiction
CN
Classification
—
Expires
2024-08-09
Drug substance claim
No
Drug product claim
No
Assignee
Nanjing Zhihe Medical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.